CAGE Bio Inc. is a biotechnology company based in San Carlos, CA, specializing in the development of innovative treatments for atopic dermatitis. Their recent clinical Phase 2 study has yielded positive results for their ionic liquid formulation of 1 Tofacitinib, offering promising prospects for patients suffering from this skin condition.
With a dedicated team of experts and cutting-edge technology, CAGE Bio Inc. aims to revolutionize the field of dermatology by providing effective solutions for atopic dermatitis. Their commitment to research and development positions them as a leading player in the biotech industry, offering hope to individuals seeking relief from the symptoms of this chronic skin disorder.
Generated from the website